Is It Safe to Reduce Inhaled Corticosteroid Dose in Severe Asthma Patients Receiving Biologic Therapy?


Özer N. O., Öztürk B. Ö., Akın B. G., Kaplankıran C., SOYYİĞİT Ş.

Clinical and Translational Allergy, cilt.16, sa.10, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 10
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1002/clt2.70204
  • Dergi Adı: Clinical and Translational Allergy
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, Directory of Open Access Journals, Academic Search Ultimate (EBSCO), Health Research Premium Collection (ProQuest)
  • Anahtar Kelimeler: asthma control, biologic therapy, inhaled corticosteroids, severe asthma, step-down treatment
  • Ankara Yıldırım Beyazıt Üniversitesi Adresli: Evet

Özet

Background: Biologic therapies can control severe asthma and may modify its natural history beyond symptom control. However, step-down is not standardized, and its safety has not been clearly established. Methods: This single-center retrospective cohort study reviewed adults with severe asthma on biologics (January 2019–May 2024). Step-down strategies (discontinuation of add-on therapy and/or inhaled corticosteroid [ICS] dose reduction) were described, success rates calculated, and clinical characteristics compared between groups with and without step-down. Results: Fifty-one patients were included, of whom 10 (19.6%) received omalizumab, 34 (66.7%) mepolizumab, and 7 (13.7%) benralizumab. After excluding 6 patients unsuitable for step-down assessment, 45 patients were compared. Step-down was attempted in 21 of these (46.7%) and succeeded in 17 (81.0%), defined as no systemic corticosteroid use, emergency visit, loss of control (ACT < 20), or exacerbation through the last visit. The most frequent interventions were ICS dose reduction (n = 7, 33.3%) and montelukast discontinuation (n = 7, 33.3%). Biologics had been received for a mean of 42.6 ± 14.0 months, and the reduced regimen was maintained for 8.15 ± 5.23 months. Compared with the non–step-down group, the step-down group had a higher proportion of males (p = 0.005) and longer follow-up (p = 0.007). Conclusion: In this real-world cohort, step-down was feasible and appeared safe, with most patients maintaining the reduced regimen without deterioration in control or exacerbations. These findings support supervised treatment minimization in carefully selected, well-controlled patients, adding real-world evidence to a limited literature.